Female Genital Schistosomiasis and HIV-1 Incidence in Zambian Women: A Retrospective Cohort Study

Amy S. Sturt,1,2 Emily L. Webb,2,3 Comfort R. Phiri,1 Maina Mudenda,4 Joyce Mapani,4 Barry Kosloff,1,3 Maina Cheeba,3 Kwame Shanaube,3 Justin Bwalya,3 Eyrun F. Kjetland,6 Suzanna C. Francis,2 Paul L. A. M. Corstjens,7 Govert J. van Dam,1,7 Lisette van Lieshout,1,7 Isaiah Hansingo,1 Helen Ayles,1,3 Richard J. Hayes,1,2 and Amaya L. Bustinduy1

1Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK, 2MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK, 3Zambart, Lusaka, Zambia, 4Department of Obstetrics and Gynaecology, Livingstone Central Hospital, Livingstone, Zambia, 5Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway, 6Discipline of Public Health, University of KwaZulu-Natal, Discipline of Public Health, Durban, South Africa, 7Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands, and 8Department of Parasitology, Leiden University Medical Center, Leiden, the Netherlands

Background. Female genital schistosomiasis (FGS) has been associated with prevalent HIV-1. We estimated the incidence of HIV-1 infection in Zambian women with and without FGS.

Methods. Women (aged 18–31, nonpregnant, sexually active) were invited to participate in this study in January–August 2018 at the final follow-up of the HPTN 071 (PopART) Population Cohort. HIV-1-negative participants at enrollment (n = 492) were included in this analysis, with testing to confirm incident HIV-1 performed in HPTN 071 (PopART). The association of incident HIV-1 infection with FGS (Schistosoma DNA detected by polymerase chain reaction [PCR] in any genital specimen) was assessed with exact Poisson regression.

Results. Incident HIV-1 infections were observed in 4.1% (20/492) of participants. Women with FGS were twice as likely to seroconvert as women without FGS but with no statistical evidence for a difference (adjusted rate ratio, 2.16; 95% CI, 0.21–12.30; P = .33). Exploratory analysis suggested an association with HIV-1 acquisition among women with ≥2 positive genital PCR specimens (rate ratio, 6.02; 95% CI, 0.58–34.96; P = .13).

Conclusions. Despite higher HIV seroconversion rates in women with FGS, there was no statistical evidence of association, possibly due to low power. Further longitudinal studies should investigate this association in a setting with higher schistosomiasis endemicity.

Keywords. HIV incidence; female genital schistosomiasis; polymerase chain reaction; PCR; parasite; Schistosoma haematobium.

In 2019, an estimated 56 million women were living with female genital schistosomiasis (FGS), a neglected tropical disease that results when eggs from the parasite Schistosoma haematobium are deposited in reproductive tract tissues [1]. Tissue-entrapped eggs incite a cellular response [2], ultimately resulting in FGS-related morbidity, including infertility [3], and distinct cervicovaginal manifestations [4, 5]. In Sub-Saharan Africa, there is a geographical association between areas of high S. haematobium prevalence and HIV-1 infection [6], and FGS has been associated with prevalent HIV-1 [7] with biological plausibility for a causal relationship [3, 8]. Despite global advances in HIV-1 treatment and prevention, gender-related disparities still exist, with particularly heightened risk among young women aged 15–24 years [9]. HIV-1 vulnerability in young women is multifactorial, including biological, behavioral, demographic, social, and structural components [10]. The potential role of FGS as an underreported and preventable co-factor in HIV-1 vulnerability needs further investigation.

Disruption of the protective vaginal and cervical epithelium by FGS-associated lesions may increase HIV-1 susceptibility by providing a portal for viral entry [3, 11]. Additionally, the environment created by S. haematobium eggs is more vascular [12], with an increased density of CD4+ lymphocytes [8] compared with non-egg-containing tissue. Thus, tissue-entrapped S. haematobium eggs create a cellular milieu that may promote HIV-1 infection. Both S. haematobium and S. mansoni infection have been associated with prevalent HIV-1 [11]. A cross-sectional study of women with FGS, defined as parasite eggs detected in genital tissue, describes a strong association with prevalent HIV-1 but no evidence of an association between urinary schistosomiasis and HIV-1 [7]. Studies primarily evaluating urinary S. haematobium (without universal evaluation for genital involvement) and prevalent HIV-1 have been mixed, with evidence of an association with prevalent HIV-1 in a study of Tanzanian women [13], some evidence of an association with prevalent HIV-1 in a study of Zimbabwean women [14], but with no evidence of an association with prevalent HIV-1 in men and women with urinary S. haematobium in Congo [15]. While S. haematobium seropositivity in women has
been associated with HIV-1 acquisition [16], the association of FGS with incident HIV-1 has not been described.

FGS diagnosis is challenging, and its burden is likely underreported. The presence of parasite eggs or DNA in cervicovaginal tissue is diagnostic of FGS [17, 18], and, historically, biopsy is used as a reference standard [4, 19]. However, theoretical concerns regarding post biopsy HIV-1 acquisition have limited the acceptance of cervical biopsy in research settings [17]. Polymerase chain reaction (PCR) on cervicovaginal lavage (CVL) is a less invasive means of FGS diagnosis, albeit with imperfect sensitivity [17, 18]. Well-defined clinical manifestations have been associated with FGS [5, 20] but are variably correlated with the presence of S. haematobium eggs [19, 20] or DNA [17] in genital tissue. The identification of clinical lesions, such as homogenous yellow sandy patches and abnormal blood vessels, with colposcopy is observer-dependent and subject to low specificity [21]. Indeed, homogenous yellow sandy patches have also been associated with herpes simplex virus–2 and human papillomavirus, and abnormal blood vessels may be associated with cervical intraepithelial neoplasia [5]. Urine microscopy and circulating anodic antigen (CAA) can be used to detect active schistosome infection [18, 22] but do not assess involvement of genital tissue. While either S. haematobium and S. mansoni can cause FGS, the majority of cases are attributed to S. haematobium [23, 24], and the current study focuses on S. haematobium. We conducted an array of diagnostic tests for S. haematobium infection (CAA and urine microscopy) and FGS (portable colposcopy, cervical swabs, vaginal swabs, and cervicovaginal lavage) and have previously demonstrated that self-collected genital swabs had comparable sensitivity to clinic-based, midwife-collected CVL for the detection of Schistosoma DNA by real-time PCR [18].

The longitudinal follow-up of women in the HPTN 071 (PopART) trial in 2 schistosomiasis-endemic communities in Zambia provided an opportunity for a nested study exploring the association of FGS with HIV-1 incidence.

METHODS

Study Setting and Participants

The cross-sectional bilharzia and HIV (BILHIV) study was nested in HPTN 071 (PopART), a cluster randomized trial assessing the impact of an HIV-1 combination prevention package including “universal testing and treatment” [25]. HIV-1 incidence was measured in a population cohort (PC) comprised of 1 randomly selected adult (18–44 years of age) from a random sample of households in each community who provided data and blood samples at baseline and at 12, 24, and 36 months [25]. Between January and August 2018, after the 36-month HPTN 071 (PopART) PC visit, trained community workers conducted home visits to women who had expressed interest in the BILHIV study [18]. Women in Livingstone, Zambia, were eligible if they were 18–31 years old, not pregnant, sexually active, and residing in 1 of the 2 urban S. haematobium–endemic communities that participated in 1 of 2 HPTN 071 (PopART) intervention arms.

Following written informed consent, the BILHIV study home visit included a questionnaire, genital self-sampling (cervical and vaginal), and a urine specimen, as previously described [18]. Within days of self-sampling, nonmenstruating participants were invited to attend Livingstone Central Hospital for cervicovaginal lavage (CVL) [18]. Cervicovaginal images were captured with a portable coloscope (MobileODT, Tel Aviv, Israel) and evaluated by 1 author (E.F.K.) for the presence of any of the 4 accepted FGS cervicovaginal manifestations: homogeneous yellow sandy patches, grainy sandy patches, rubbery papules, and abnormal blood vessels [26]. Women with evidence of schistosome infection by colposcopy [26] or any positive urine or genital diagnostic were treated free of charge with 40 mg/kg of praziquantel. Routine testing for sexually transmitted infections (STIs) was not performed. Participants with suspected STI were offered syndromic management, as per local guidelines [27].

HIV-1

Laboratory-based fourth-generation HIV-1 testing (Abbott Architect HIV Ag/Ab ComboAssay, Wiesbaden, Germany) was performed for HPTN 071 (PopART) PC participants at each study visit [25]. Additional testing using antigen/antibody screening tests, a discriminatory test, and an HIV-1 RNA test was used to confirm incident HIV-1 infection, as previously described [28].

Circulating Anodic Antigen

CAA levels reflect the burden of live schistosomes and decline after successful treatment with praziquantel [22, 29]. An up-converting reporter particle lateral flow assay for the quantification of CAA in urine was performed at the Leiden University Medical Center (LUMC), as previously described [18, 30]. Analyzing the equivalent of 417 μL of urine, a CAA value of >0.6 pg/mL was considered positive [22].

PCR for Detection of Schistosoma DNA

DNA extraction and PCR was performed at LUMC as previously described, using a custom automated liquid handling station (Hamilton, Switzerland) [20, 31]. DNA was extracted from 200 μL of specimen (cervical swab, vaginal swab, CVL) with QIAamp spin columns (QIAGEN Benelux, Venlo, the Netherlands). Detection of the schistosome-specific internal-transcribed-spacer-2 (ITS2) target was performed by real-time PCR as previously described [18, 31]. This PCR does not differentiate between Schistosoma species. DNA amplification and detection were performed with the CFX96 Real Time PCR Detection System (BioRad, Hercules, CA, USA). The output in threshold cycles (Cts), reflecting the parasite-specific DNA
load in the tested sample, was analyzed using BioRad CFX software. Parasite DNA loads were categorized by the following prespecified \( C_t \) thresholds: high (\( C_t < 30 \)), moderate (\( 30 \leq C_t < 35 \)), low (\( 35 \leq C_t < 50 \)), and negative (no \( C_t \) detected), as previously described [32].

**Patient Consent**

This study was approved by the University of Zambia Biomedical Research Ethics Committee (reference 011-08-17), the Zambia National Health Research Authority, and the London School of Hygiene and Tropical Medicine Ethics Committee (reference 14506). Permission to conduct the study was given by the Livingstone District Health Office and the Livingstone Central Hospital superintendent. Each participant provided written informed consent.

**FGS Definitions**

Comparison groups were defined by the results of 4 investigations: genital PCR, colposcopy image review, urine CAA, and urine microscopy. Participants were grouped by the outcomes of their diagnostic tests into 3 mutually exclusive categories. FGS was defined as at least 1 positive genital PCR (cervical swab, vaginal swab, or CVL) (Figure 1). Probable/possible FGS was defined as the presence of either a positive urine diagnostic (CAA or microscopy) or 1 of 4 cervicovaginal manifestations suggestive of FGS on portable colposcopy, or both, with negative genital PCR (Figure 1). FGS negative was defined as negative results on all diagnostics.

**Statistical Methods**

Characteristics of study participants were summarized by frequency and percentage. Women with HIV-1 (WWH) at HPTN 071 (PopART) baseline were excluded from further analyses. HIV-1 incidence was calculated as the number of seroconversions per 1000 person-years of follow-up. Participants contributed person-time for the calculation of HIV-1 incidence starting with their first HIV-1 test and ending at the date of HIV-1 seroconversion for those who seroconverted, or at the date of last follow-up or the end of scheduled follow-up (whichever

![Figure 1](https://academic.oup.com/ofid/article/8/7/ofab349/6311690)
occurred earliest) for women who did not seroconvert. HIV-1 seroconversion was assumed to occur at the midpoint between the last negative and the first positive HIV-1 test. We assumed that FGS acquisition occurred before HPTN 071 (PopART) enrollment [33]. BILHIV study participants were consecutively recruited from the PC, providing the opportunity to compare the rate of incident HIV-1 infection in women with and without FGS, with power determined by the number of HIV-1 seroconversions and FGS prevalence. Data on HIV-1 outcomes were not available until after BILHIV study closure.

Associations of risk factors with incident HIV-1 infection were calculated as rate ratios and 95% confidence intervals, estimated using exact Poisson regression in univariable and multivariable analysis. We used a causal conceptual framework to inform our choice of potential confounders. A priori, we included age as a confounding variable. Due to loss of precision with further adjustment for potential confounding variables, no additional parameters were included in the multivariable model. To assess the primary exposure of interest, women with FGS (n = 26) were compared with an FGS-negative comparison group comprising those who were negative on all diagnostic investigations (n = 218). Participants who were negative on all diagnostic investigations but missing colposcopy images (n = 82) were excluded from the primary analysis.

To evaluate the association of schistosome infection intensity with HIV-1 seroconversion, 2 ad hoc exploratory analyses were performed. One compared participants with FGS and a moderate/high Schistosoma DNA concentration (Ct < 35) with those in the FGS-negative group. The second compared participants with FGS with ≥2 positive genital PCR specimens with those in the FGS-negative group. Data were analyzed using STATA 15.1 (Stata Corporation, College Station, TX, USA).

RESULTS
A total of 603 eligible women from the HPTN 071 Population Cohort were enrolled in the BILHIV study. WWH at HPTN 071 (PopART) trial entry (n = 107, 17.7%) were excluded, with 492 (82.1%) included in this analysis (Figure 2). Of the included participants, 14% (69/492) did not attend clinic for CVL.

Baseline Characteristics
The majority of participants had received at least secondary education, were not working, and reported being currently sexually active. A small proportion of women reported current water contact, but more than half reported childhood water contact. Active schistosome infection, defined as either a positive urine microscopy (5.5%, 27/492) or detectable CAA (15.1%, 74/492), was detected in 15.7% (77/492) of participants.

![Figure 2](https://academic.oup.com/ofid/article-lookup/70f5a3e86316390)
The 492 women without HIV-1 at HPTN 071 (PopART) study entry provided a total of 1164 person-years of follow-up, during which time 20 (4.1%) incident HIV-1 infections were measured, for an overall rate of 17.2 (95% CI, 11.1–26.6) seroconversions per 1000 person-years. HIV-1 incidence rates are shown by baseline characteristics in Table 1.

HIV-1 incidence rates were 23.6 (14.2–39.2) in women aged 18–24 years compared with 9.5 (3.9–22.7) in women aged 25–31 (rate ratio [RR], 0.40; 95% CI, 0.15–1.10; P = .06) (Table 1). The HIV-1 seroconversion rate decreased as the household size increased (P = .007, test for trend) and increased as the number of lifetime sexual partners increased (P = .01, test for trend). Women self-reporting a history of STI were more likely to seroconvert than women without self-reported STI (RR, 6.05; 95% CI, 2.02–17.22; P = .009) (Table 1). No other sociodemographic or behavioral characteristics were associated with HIV-1 incidence. After adjusting for age, there remained strong evidence that a lower number of people residing in a household (P = .008, test for trend), a higher number of lifetime sexual partners (P = .01, test for trend), and self-reported history of STI (aRR, 6.05; 95% CI, 2.02–18.12; P = .008) were associated with HIV-1 seroconversion. Additionally, there was no evidence of an association between urinary schistosome infection (as defined by urine CAA and/or microscopy) and HIV-1 seroconversion (Table 2).

**Association Between FGS and HIV-1 Seroconversion**

FGS was identified in 5.3% of women (26/492), defined as any positive genital PCR (cervical swab 3.5% [17/492]; vaginal swab 2.4% [12/492]; or CVL 3.1% [13/423]). Among women with a negative genital PCR, results from both urine and colposcopy imaging were positive in 4.5% (21/466) of participants, and results from either urine or colposcopy imaging were positive in 31.1% (145/466). Of the participants with probable/possible FGS, 63.8% (106/166) had colposcopy changes in isolation (Figure 1), of whom 62.3% (66/106) had abnormal blood vessels and 37.7% (40/106) had grainy or homogenous yellow sandy patches on colposcopy. There were 218 (44.3%) participants who were negative on all diagnostic tests. The rate of HIV-1 seroconversion (per 1000 person/year) in women with FGS (31.0 [7.8–123.9]) was higher than in the FGS-negative group (11.3 [5.1–25.1]) (Table 2) but without statistical evidence of a difference between these rates in either univariable or multivariable analyses (crude RR, 2.75; 95% CI, 0.27–15.36; P = .26; aRR, 2.16; 95% CI, 0.21–12.30; P = .33) (Table 2).

**Exploratory Analyses: Schistosoma DNA Concentrations and Disease Burden**

In the ad hoc exploratory analysis of women (n = 13) with FGS and moderate/high Schistosoma DNA concentrations, the IRR for HIV-1 acquisition after adjusting for age was 4.73 (0.46–27.05; P = .19) compared with FGS-negative participants (Table 2). In an ad hoc exploratory analysis of women (n = 13) with ≥2 positive genital PCR specimens compared with FGS-negative participants, the IRR for HIV-1 acquisition after adjusting for age was 6.02 (0.58–34.96; P = .13) (Table 2). In these groups, n = 9 of the women overlapped and the same 2 participants contributed seroconversions in both groups. There were no HIV-1 seroconversions in participants with 1 positive genital PCR.

**DISCUSSION**

This study is the first to examine the association of PCR-defined FGS with HIV-1 incidence. While barriers to implementation still exist, PCR for Schistosoma DNA detection in FGS diagnosis is reproducible, has high specificity, and can be performed on self-collected genital specimens [18]. We found that women with FGS were twice as likely to seroconvert than women in the comparison group, albeit with wide confidence intervals and no statistical evidence for a difference.

While some cross-sectional studies show an association between schistosomiasis and prevalent HIV-1 infection [13, 23], this association is not universally reported [34, 35]. The association between schistosomiasis and HIV-1 is complex and cross-study comparisons require consideration of many aspects, including schistosome species (S. haematobium vs S. mansoni), diagnostic tests used, assessment of genital involvement, and presentation of subgroup analyses, for example, by participant sex. Our findings, while limited by power, show a point estimate consistent with increased risk of incident HIV-1, but with a wide confidence interval. Recently, 2 case–control studies nested within longitudinal African cohorts have retrospectively assessed the association between schistosomiasis infection status and HIV-1 seroconversion, with conflicting results [16, 36]. A Zambian study showed an increased risk of HIV-1 acquisition in S. haematobium antibody–positive women (adjusted hazard ratio, 1.4; P < .05), but not men [16]. Similar to our results, a study from Kenya and Uganda did not show an association between active schistosome infection and HIV-1 seroconversion, including in subgroup analyses by sex, schistosome species, and infection intensity [36]. Notably, however, neither of these nested case–control studies evaluated genital infection status. FGS may enhance HIV-1 vulnerability, with proposed mechanisms including cervicovaginal barrier dysfunction [37], local recruitment or activation of HIV-1 target cells [3], and Schistosoma–related alterations in integrin [38] or co-receptor [39] expression.

Schistosomiasis and FGS are preventable, and current World Health Organization control measures recommend praziquantel preventive chemotherapy [40]. However, current control programs do not universally achieve 75% coverage of school-aged children, representing substantial missed opportunities.
Table 1. HIV-1 Seroconversion Rates by Baseline BILHIV Study Characteristic in 492 Zambian Women

| Sociobehavioral Characteristics | No. (%) | Events | Rate of HIV Seroconversion per 1000 p/y | Crude IRR (95% CI) | P Value |
|-------------------------------|---------|--------|----------------------------------------|---------------------|---------|
| **Age, y**                    |         |        |                                        |                     |         |
| 18–24                         | 289 (58.7) | 15     | 23.6 (14.2–39.2)                       | Reference           | .06     |
| 25–31                         | 203 (41.3)  | 5      | 9.5 (3.9–22.7)                        | 0.40 (0.15–1.00)   |         |
| **Marital status**            |         |        |                                        |                     |         |
| Single                        | 219 (44.5)  | 12     | 23.0 (13.1–40.9)                       | Reference           | .35     |
| Married or cohabitating       | 255 (51.8)  | 7      | 11.8 (5.6–24.7)                       | 0.51 (0.20–1.30)   |         |
| Widowed, divorced, or separated| 18 (3.7)   | 7      | 21.2 (6.0–50.8)                       | 0.32 (0.12–1.0)    |         |
| **Education (highest level)** |         |        |                                        |                     |         |
| None or any primary school    | 137 (27.9)  | 5      | 15.7 (5.5–37.6)                       | Reference           | .57     |
| Any secondary school          | 207 (41.4)  | 11     | 15.5 (6.2–28.0)                       | 0.99 (0.34–2.85)   |         |
| Trade, degree or higher       | 58 (11.8)   | 4      | 29.4 (11.0–78.4)                      | 1.88 (0.50–7.00)   |         |
| **District**                  |         |        |                                        |                     |         |
| Community A                   | 260 (52.9)  | 11     | 15.5 (6.2–26.0)                       | Reference           | .90     |
| Community B                   | 232 (47.1)  | 9      | 19.8 (10.3–38.0)                      | 1.27 (0.52–3.07)   |         |
| **Household members**         |         |        |                                        |                     |         |
| 1–3                           | 141 (28.7)  | 12     | 38.4 (18.2–76.8)                      | Reference           | .007    |
| 4–5                           | 201 (40.9)  | 4      | 8.2 (1.1–21.7)                        | 0.21 (0.07–0.66)   |         |
| 6+                            | 150 (30.5)  | 4      | 11.1 (4.2–29.9)                       | 0.29 (0.09–0.90)   |         |
| **Employment status**         |         |        |                                        |                     |         |
| Not working                   | 327 (66.5)  | 13     | 171 (10.0–29.5)                       | Reference           | .99     |
| Working                       | 165 (33.5)  | 7      | 173 (8.2–36.2)                       | 101 (0.40–2.52)    |         |
| **Sexual behavior characteristics** |     |        |                                        |                     |         |
| **Age at sexual debut, y**    |         |        |                                        |                     |         |
| 8–16                          | 197 (40.0)  | 9      | 20.6 (10.7–39.9)                      | Reference           | .79     |
| 17–19                         | 220 (44.7)  | 8      | 14.9 (7.5–29.3)                       | 0.73 (0.38–188)    |         |
| 20–24                         | 75 (15.2)   | 3      | 15.7 (5.1–48.8)                       | 0.77 (0.21–2.83)   |         |
| **Lifetime sexual partners**  |         |        |                                        |                     |         |
| 1                             | 149 (30.3)  | 2      | 5.7 (1.4–22.9)                        | Reference           | .01     |
| 2                             | 134 (27.2)  | 5      | 15.9 (5.6–38.3)                       | 2.78 (0.54–14.34)  |         |
| 3                             | 103 (20.9)  | 5      | 18.7 (7.8–45.0)                       | 3.27 (0.63–16.85)  |         |
| 4+                            | 106 (21.5)  | 8      | 34.1 (17.1–68.2)                      | 5.95 (1.26–28.02)  |         |
| **Currently sexually active**  |         |        |                                        |                     |         |
| No                            | 63 (12.8)   | 3      | 20.1 (5.5–62.4)                       | Reference           | .78     |
| Yes                           | 427 (87.1)  | 17     | 16.9 (10.5–27.1)                      | 0.84 (0.35–2.86)   |         |
| **STI history**               |         |        |                                        |                     | .003    |
| No                            | 466 (94.9)  | 16     | 14.4 (8.8–23.9)                       | Reference           |         |
| Yes                           | 25 (5.1)    | 4      | 82.8 (31.1–220.5)                     | 5.76 (192–722)     |         |
| **Condom use with last sex**  |         |        |                                        |                     | .11     |
| No                            | 367 (75.8)  | 12     | 13.8 (7.9–24.3)                       | Reference           |         |
| Yes                           | 117 (24.2)  | 8      | 29.2 (14.6–58.3)                      | 2.11 (0.86–5.16)   |         |
| **Contraceptive use**         |         |        |                                        |                     |         |
| Condoms                       |         |        |                                        |                     |         |
| No                            | 407 (82.7)  | 14     | 14.8 (8.8–25.0)                       | Reference           | .23     |
| Yes                           | 85 (17.3)   | 6      | 275 (12.4–612)                       | 1.86 (0.71–4.83)   |         |
| **OCP**                       |         |        |                                        |                     | .96     |
| No                            | 440 (89.4)  | 18     | 173 (10.3–274)                       | Reference           |         |
| Yes                           | 52 (10.6)   | 2      | 16.6 (4.1–66.3)                       | 0.96 (0.22–4.14)   |         |
| **Injectable**                |         |        |                                        |                     | .13     |
| No                            | 225 (45.7)  | 14     | 22.5 (13.4–38.1)                      | Reference           |         |
| Yes                           | 267 (54.3)  | 6      | 11.1 (5.0–24.8)                       | 0.49 (0.19–1.28)   |         |
| **Implant**                   |         |        |                                        |                     | .37     |
| No                            | 466 (94.7)  | 18     | 16.3 (10.3–25.9)                      | Reference           |         |
| Yes                           | 26 (5.3)    | 2      | 34.0 (9.5–135.8)                      | 2.10 (0.48–8.99)   |         |

Abbreviations: BILHIV, cross-sectional bilharzia and HIV study; IRR, incidence rate ratio; OCP, oral contraceptive pill; STI, sexually transmitted infection.

*Test for trend P value.

1Any sexual activity in the last 6 months.

2Participants who responded with “no answer” (n = 2) are not shown in the table (HIV seroconversions = 0).

3STI history was self-reported; participants who responded with “no answer” (n = 1) are not shown (HIV seroconversions = 0).

4Participants who responded with “no answer” (n = 8) are not shown in the table (HIV seroconversions = 0).

5Participants who responded with “no answer” (n = 2) are not shown in the table (HIV seroconversions = 0).
Table 2. HIV-1 Incidence by FGS Status and Schistosomiasis-Related Factors

| Category                        | No. (%) | Incident HIV Cases | Total PY | Rate per 1000 PY (95% CI) | IRR (95% CI) | PValue | aRRa | PValue |
|---------------------------------|---------|--------------------|----------|---------------------------|--------------|--------|------|--------|
| FGS negativeb                   | 218 (53.2) | 6                  | 532.0    | 11.3 (5.1–25.1)          | Reference    | .26    | Reference | .33    |
| Probable/possible FGS           | 166 (40.5) | 7                  | 372.2    | 18.8 (9.0–39.5)      | 1.67 (0.48–6.01) | 1.73 (0.50–6.22) |
| FGS                             | 26 (6.3) | 2                  | 64.5     | 31.0 (7.8–123.9)       | 2.75 (0.27–15.36) | 2.16 (0.21–12.30) |
| **Exploratory analysis of participants with FGS** | | | | | | | | |
| FGS negative                    | 218     | 6                  | 532.0    | 11.3 (5.1–25.1)           | Reference    | .09    | Reference | .13    |
| FGS and 2-3 PCR positived       | 13      | 2                  | 24.9     | 80.4 (20.1–321.7)        | 7.13 (0.70–39.89) | 6.02 (0.58–34.96) |
| FGS negative                    | 218     | 6                  | 532.0    | 11.3 (5.1–25.1)           | Reference    | .15    | Reference | .19    |
| FGS and PCR Ct <35e             | 13      | 2                  | 32.6     | 61.31 (15.33–245.14)     | 5.44 (0.54–30.40) | 4.73 (0.46–27.05) |
| **Schistosomiasis-related factors** | | | | | | | | |
| Urine microscopy negative       | 465 (94.5) | 18                | 1102.4   | 16.3 (10.3–25.9)         | Reference    | .40    | Reference | .47    |
| Urine microscopy positive       | 27 (5.5) | 2                  | 616.0    | 32.5 (8.1–129.9)        | 1.98 (0.46–8.58) | 1.78 (0.41–7.71) |
| Urine CAA not detectable        | 416 (84.9) | 16               | 993.5    | 16.1 (9.9–26.3)         | Reference    | .86    | Reference | .78    |
| Urine CAA detectable            | 74 (15.1) | 3                  | 166.6    | 18.0 (5.8–55.8)         | 1.12 (0.33–3.84) | 1.19 (0.35–4.10) |
| Active infection not present    | 413 (84.3) | 16               | 985.0    | 16.2 (10.0–26.5)        | Reference    | .93    | Reference | .85    |
| Active infection present        | 77 (15.7) | 3                  | 175.1    | 17.1 (5.5–53.1)         | 1.05 (0.31–3.62) | 1.13 (0.33–3.88) |

Abbreviations: aRR, adjusted rate ratio; CAA, circulating anodic antigen; Ct, cycle threshold; FGS, female genital schistosomiasis; IRR, incidence rate ratio; PCR, polymerase chain reaction; PY, person-years; RR, rate ratio.

aAdjusted for age.
bEighty-two participants who were negative on all diagnostic tests but missing portable colposcopy images were excluded from this analysis.
cTest for trend P value (RR per unit of the exposure variable [FGS negative, probable/possible FGS, and FGS] treated as a continuous variable).
dn = 13 excluded (1 genital PCR specimen positive).
eIn Ct >35.
fIn Ct >35.
gActive infection defined as detectable urine CAA or positive urine microscopy.
for prevention [41, 42]. The 2025 AIDS targets place communities at risk for HIV-1 in the center of societal, system, and service enablers with a call for between-sector integration and synergy to advance the HIV-1 response [43]. Programmatic synergy including integrated sexual and reproductive health programs could leverage and scale-up existing HIV-1 treatment and prevention resources to include FGS screening and treatment programs.

We carried out 2 ad hoc exploratory analyses. The intensity of schistosome infection, defined by serum CAA concentration, has been strongly correlated with HIV-1 prevalence [13]. Thus, first, we investigated whether Schistosoma DNA concentrations might be associated with HIV-1 infection in an analysis of 13 participants with FGS and moderate/high Schistosoma DNA concentrations. We found no evidence of an association between FGS and HIV-1 acquisition, albeit with wide confidence intervals. Additionally, participants with moderate-to-high-intensity seminal egg excretion have higher seminal cytokine concentrations than S. haematobium–negative participants [44]. Thus, secondly, we investigated the association between multiple positive genital PCR specimens as a potential proxy marker of higher FGS burden and HIV-1 seroconversion in 13 women with ≥2 positive genital specimens for Schistosoma DNA. We found weak evidence of an association between FGS and HIV-1 acquisition, which was less pronounced in the age-adjusted estimates. These findings are hypothesis-generating for the association between FGS cervicovaginal disease burden or Schistosoma DNA concentrations and HIV-1.

This study was nested within a large population-based HIV-1 prevention trial and is the first prospective study to document FGS in Zambia, but it also had some relevant limitations. Similar to other FGS studies using imperfect available diagnostics, there is the risk of potential diagnostic misclassification, especially in this low-prevalence setting. We defined FGS by PCR positivity based on its semiquantitative nature and precedent in FGS diagnosis [17, 18, 45]. However, S. haematobium eggs in semen from a male sex partner could potentially be detected by PCR of vaginal specimens. We were unable to adjust for potential confounders beyond age and are thus unable to exclude unmeasured and residual confounding. This was related to the low number of HIV-1 seroconversions and FGS cases, which also resulted in a loss of power. Overall, the effect sizes suggest the possibility of a relationship we were not sufficiently powered to detect. While the prevalence of HIV-1 in the study population was high at 17.9%, the 2 participating communities were enrolled in HPTN 071 (PopART) as intervention sites, potentially reducing the number of HIV-1 seroconversions [25]. The prevalence of urinary S. haematobium infection in this study was 5.5% (27/492), lower than anticipated, defined by the World Health Organization as a low-prevalence area (<10% S. haematobium prevalence) [46]. Indeed, a 2013 survey done by the Zambian Ministry of Health reported a wide range of egg-patent prevalence in Livingstone, ranging from 3.3% to 73.3% (median, 15.0%; mean, 23.3%) in school-aged children, highlighting its focal distribution [47]. In addition, while schistosomiasis is endemic in all of Zambia’s 10 provinces [48] and can be found in urban locations, it is generally considered to be a focal disease of rural areas [49]. For all the above reasons, the presented estimates, obtained in a peri-urban setting, are subject to a high degree of imprecision and may not be generalizable to rural communities. Lastly, vaginal and cervical swabs were self-collected by participants, raising the potential for false-negative genital swabs. In future work, this could be addressed by measuring β-globin PCR as a positive control to confirm the presence of human DNA [50]. This study was developed based on a conceptual framework that describes a potentially causal relationship between FGS and HIV-1, with FGS as a potentially preventable and modifiable risk factor. In the literature, albeit in cross-sectional studies, there is evidence for biological plausibility [3, 8, 12] and large effect sizes for the association [7] between FGS and HIV-1. One of our study limitations was the temporality of HIV-1 and FGS diagnostics. HIV-1 seroconversion was measured in HPTN 071 (PopART) up to 3 years before participant enrollment in the study and subsequent FGS diagnosis. This sequencing assumes that FGS status and demographic descriptors at the time of genital PCR sampling are similar to those at the time of HPTN 071 (PopART) study entry and/or HIV-1 seroconversion. This assumption is reasonable given that FGS is thought to develop after childhood water exposure [33] and persist into adulthood with chronic genital lesions, often persisting despite treatment with praziquantel [51]. A large, prospective, longitudinal study in areas of higher S. haematobium endemity is needed to evaluate incident HIV-1 infection in women with known S. haematobium and FGS status at study baseline. In future work, it will be important to continue to analyze HIV-1 outcomes by both S. haematobium infection status and FGS definition (PCR vs clinical findings) to evaluate HIV-1 risk profiles.

In conclusion, this analysis does not show evidence of association between FGS and HIV-1 incidence. The hypothesis-generating observations that FGS, and in particular higher FGS cervicovaginal disease burden or Schistosoma DNA concentrations, may be associated with HIV-1 acquisition should be investigated in a larger longitudinal study in a high–FGS prevalence area to better explore the role of FGS in HIV-1 acquisition.

Acknowledgments

We wish to acknowledge the study participants, without whom this work would not be possible. We would like to recognize the work performed by the BILHIV supervisor Namakau Chola and the BILHIV community workers Ethel Mwansa, Mwiingana Lukonga, Ruth Mwanza, Mervis Kantukaleza, and Judith Lungu. We also acknowledge tremendous support in Livingstone from Clement Mwakamui (Zambart) and Tobias Mweene (Zambart). We gratefully acknowledge Eric A. T. Brienen (LUMC) for performing the genital PCR analysis and Claudia I. de Doed (LUMC) and Pytje T. Hoekstra (LUMC) for performing the CAA analysis.
Financial support. Amaya Bustinduy received funding from the Wellcome Trust (Award 209594/Z/17/Z). Dr. E. Webb and Professor R. Hayes received funding from MRC Grant Reference MR/K012126/1 and Dr. S. C. Francis received a salary from MRC Grant Reference MR/N023692/1. These awards are jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, which is also part of the EDCTP2 program supported by the European Union. HPTN 071 (PopART) was supported by the National Institute of Allergy and Infectious Diseases (NIAID) under Cooperative Agreements UM1-A1068619, UM1-A1068617, and UM1-A1068613, with funding from the US President's Emergency Plan for AIDS Relief (PEPFAR); the International Initiative for Impact Evaluation with support from the Bill and Melinda Gates Foundation; the NIAID, the National Institute on Drug Abuse, and the National Institute of Mental Health, all part of the National Institutes of Health. Professor Eyrun Kjeldgaard was supported by South-Eastern Regional Health Authority, Norway project #2016055.

Potential conflicts of interest. The authors report no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Author contributions. Amy S. Sturt – conceptualization, data curation, formal analysis, BILHIV project administration, supervision, original manuscript preparation, manuscript editing and revision. Emily L. Webb – conceptualization, data curation, formal analysis, supervision, visualization, original manuscript preparation, manuscript editing and revison. Amaya L. Bustinduy – conceptualization, formal analysis, writing – review and editing. Amaya L. Bustinduy – conceptualization, funding acquisition, supervision, original manuscript preparation, manuscript editing and revision. Joyce Mapani – writing – review and editing. Barry Kosloff – conceptualization, data curation, formal analysis, BILHIV project administration, supervision, visualization, original manuscript preparation, manuscript editing and revision. Kwame Shanube – HPTN 071 (PopART) project administration, investigation, writing – review and editing. Barry Kosloff – conceptualization, data curation, formal analysis, BILHIV project administration, supervision, visualization, original manuscript preparation, manuscript editing and revision. Comfort R. Phiri – BILHIV project administration, writing – review and editing. Maina Mudenda – investigation, writing – review and editing. Joyce Mapani – investigation, writing – review and editing. Barry Kosloff – conceptualization, resources, HPTN 071 (PopART) project administration, investigation, writing – review and editing. Justice Maunde – investigation, writing – review and editing. Emily L. Webb – conceptualization, data curation, formal analysis, supervision, original manuscript preparation, manuscript editing and revision. Paul L. A. M. Corstjens – investigation, writing – review and editing. Gover J. van Dam – investigation, writing – review and editing. Simatani Makanda – investigation, writing – review and editing. Sadie Chibwana – conceptualization, resources, supervision, writing – review and editing. Helen Ayles – conceptualization, resources, supervision, writing – review and editing. Richard J. Hayes – conceptualization, resources, supervision, formal analysis, writing – review and editing. Amya L. Bustinduy – conceptualization, funding acquisition, supervision, original manuscript preparation, manuscript editing and revision.

Financial support. Amaya Bustinduy received funding from the Wellcome Trust (Award 209594/Z/17/Z). Dr. E. Webb and Professor R. Hayes received funding from MRC Grant Reference MR/K012126/1 and Dr. S. C. Francis received a salary from MRC Grant Reference MR/N023692/1. These awards are jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, which is also part of the EDCTP2 program supported by the European Union. HPTN 071 (PopART) was supported by the National Institute of Allergy and Infectious Diseases (NIAID) under Cooperative Agreements UM1-A1068619, UM1-A1068617, and UM1-A1068613, with funding from the US President’s Emergency Plan for AIDS Relief (PEPFAR); the International Initiative for Impact Evaluation with support from the Bill and Melinda Gates Foundation; the NIAID, the National Institute on Drug Abuse, and the National Institute of Mental Health, all part of the National Institutes of Health. Professor Eyrun Kjeldgaard was supported by South-Eastern Regional Health Authority, Norway project #2016055.

Potential conflicts of interest. The authors report no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Author contributions. Amy S. Sturt – conceptualization, data curation, formal analysis, BILHIV project administration, supervision, original manuscript preparation, manuscript editing and revision. Emily L. Webb – conceptualization, data curation, formal analysis, supervision, visualization, original manuscript preparation, manuscript editing and revision. Comfort R. Phiri – BILHIV project administration, writing – review and editing. Maina Mudenda – investigation, writing – review and editing. Joyce Mapani – investigation, writing – review and editing. Barry Kosloff – conceptualization, resources, HPTN 071 (PopART) project administration, investigation, writing – review and editing. Kwame Shanube – HPTN 071 (PopART) project administration, writing – review and editing. Justin Bwalya – HPTN 071 (PopART) project administration, writing – review and editing. Eyrun F. Kjeldgaard – investigation, writing – review and editing. Suzanna C. Francis – conceptualization, supervision, original manuscript preparation, manuscript editing and revision. Paul L. A. M. Corstjens – investigation, writing – review and editing. Gover J. van Dam – investigation, writing – review and editing. Simatani Makanda – investigation, writing – review and editing. Isisah Hansingo – conceptualization, resources, supervision, writing – review and editing. Helen Ayles – conceptualization, resources, supervision, writing – review and editing. Richard J. Hayes – conceptualization, resources, supervision, formal analysis, writing – review and editing. Amya L. Bustinduy – conceptualization, funding acquisition, supervision, original manuscript preparation, manuscript editing and revision.

References
1. UNAIDS. No more neglect — female genital schistosomiasis and HIV — integrating sexual and reproductive health interventions to improve women’s lives, 2019. Available at: https://www.unaids.org/en/resources/documents/2019/fem-male genital_schistosomiasis_and_hiv. Accessed 30 April 2021.
2. Odegard Jr, Hsieh MH. Immune responses to Schistosoma haematobium infection. Parasite Immunol 2014; 36:428–38.
3. Sturt AS, Webb EL, Francis SC, Hayes RJ, Bustinduy AL. Beyond the barrier: female genital schistosomiasis as a potential risk factor for HIV-1 acquisition. Acta Trop 2020; 209:105524.
4. Poggensee G, Kiwelo I, Weger V, et al. Female genital schistosomiasis of the lower genital tract: prevalence and disease-associated morbidity in Northern Tanzania. Trop Med Int Health 2006; 11:822–9.
5. Jourdan PM, Holmen SD, Gundersen SG, Roald B, Kjetland EF. HIV target cells in Schistosoma haematobium-infected female genital mucosa. Am J Trop Med Hyg 2011; 85:1060–4.
6. UNAIDS. UNAIDS global AIDS update, communities at the centre 2019. Available at: https://www.unaids.org/en/resources/documents/2019/fe-gra-tion_of_schistosomiasis-and_HIV_infection_rural_Zimbabwe: does age matter?. Trans R Soc Trop Med Hyg 2007; 101:433–8.
7. N’Zoukoudi-N’Doundou MY, Dirat A, Akoaala J, Penchenier L, Makura M, Rey JL. Bilharziasis and human immunodeficiency virus infection in Congo. Med Trop 1995; 55:249–51.
8. Wall KM, Kilembe W, Vwalika B, et al. Schistosomiasis is associated with incident HIV transmission and death in Zambia. PLoS Negl Trop Dis 2018; 12:e0006902.
9. Kjetland EF, Hove RJ, Goméx, et al. Schistosomiasis is associated with HIV infection in rural Zambian women. Am J Trop Med Hyg 2009; 81:1050–5.
10. Sturt AS, Webb EL, Phiri CR, et al. Genital self-sampling compared with cervicovaginal lavage for the diagnosis of female genital schistosomiasis in Zambian women: the BILHIV study. PLoS Negl Trop Dis 2014; 8:e300837.
11. Leutscher P, Ravaolimalalala VE, Raharisoa C, et al. Clinical findings in female genital schistosomiasis in Madagascar. Trop Med Int Health 1998; 3:327–32.
12. Ndoumbou BS, Jourdan PM, Ramoniaminina F, et al. Gynecological manifestations, histopathological findings, and Schistosoma-specific polymerase chain reaction results among women with Schistosoma haematobium infection: a cross-sectional study in Madagascar. J Infect Dis 2015; 212:275–84.
13. Galappaththi-Arachchige HN, Holmen S, Kourouani A, et al. Evaluating diagnostic indicators of urogenital Schistosoma haematobium infection in young women: a cross-sectional study in rural South Africa. PLoS One 2018; 13:e0191459.
14. Bajwa S, Zorzi G, Zorzi G, et al. Circulating anodic antigen (CAA): a highly sensitive diagnostic biomarker to detect active Schistosoma infections-improvement and use during score. Am J Trop Med Hyg 2020; 103:50–7.
15. Downs JA, Mguta C, Kaatano GM, et al. Urogenital schistosomiasis in women of reproductive age in Tanzania’s Lake Victoria region. Am J Trop Med Hyg 2011; 84:364–9.
16. Wright ED, Chiphangwe J, Hutt MS. Schistosomiasis of the female genital tract. A histopathological study of 176 cases from Malawi. Trans R Soc Trop Med Hyg 1982; 76:822–9.
17. Hayes RJ, Donnell N, Ford S, et al. Effect of universal testing and treatment on HIV incidence - HPTN 071 (PopART). N Engl J Med 2019; 381:207–18.
18. World Health Organization. Female genital schistosomiasis: a pocket atlas for clinical health-care professionals. 2015. Available at: http://www.who.int/iris/handle/10665/180863. Accessed 30 April 2021.
19. Zambian Ministry of Health. Guidelines for the Etiological and Clinical Management of Sexually Transmitted Infections in Zambia. 2017.
20. Nyame MA, Chomba C, Chipata C, et al. Association between genital schistosomiasis and HIV in rural Zambian women. AIDS 2006; 20:593–600.
33. Hegertun IE, Sulheim Gundersen KM, Kleppa E, et al. *S. haematobium* as a common cause of genital morbidity in girls: a cross-sectional study of children in South Africa. PLoS Negl Trop Dis 2013; 7:e2104.

34. Kapiga S, Hansen CH, Downs JA, et al. The burden of HIV, syphilis and schistosome infection and associated factors among adults in the fishing communities in Northwestern Tanzania. Trop Med Int Health 2021; 26:204–13.

35. Sanya RE, Muhangi L, Nampijja M, et al. *Schistosoma mansoni* and HIV infection in a Ugandan population with high HIV and helminth prevalence. Trop Med Int Health 2015; 20:1201–8.

36. Bochner AF, Baeten JM, Secor WE, et al. Associations between schistosomiasis and HIV-1 acquisition risk in four prospective cohorts: a nested case-control analysis. J Int AIDS Soc 2020; 23:e25534.

37. Feldmeier H, Krantz I, Poggensee G. Female genital schistosomiasis: a neglected risk factor for the transmission of HIV? Trans R Soc Trop Med Hyg 1995; 89:237.

38. Yegorov S, Joag V, Galiwango RM, et al. *Schistosoma mansoni* treatment reduces HIV entry into cervical CD4+ T cells and induces IFN-I pathways. Nat Commun 2019; 10:2296.

39. Kleppa E, Ramsuran V, Zulu S, et al. Effect of female genital schistosomiasis and anti-schistosomal treatment on monocytes, CD4+ T-cells and CCR5 expression in the female genital tract. PLoS One 2014; 9:e98593.

40. World Health Organization. Schistosomiasis. Control and preventive chemotherapy. Available at https://www.who.int/schistosomiasis/strategy/en/. Accessed 30 April 2021.

41. World Health Organization. Schistosomiasis and soil-transmitted helminthiasis: number of people treated in 2016. Available at: https://www.who.int/neglected_diseases/resources/who_wer9249/en/. Accessed 30 April 2021.

42. World Health Organization. Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. 2006. Available at: https://apps.who.int/iris/bitstream/handle/10665/43545/9241547103_eng.pdf;jsessionid=564247BFBA426C9BD72B1048671034F?sequence=1. Accessed 30 April 2021.

43. Kalinda C, Chimbari MJ, Mukaratirwa S. Schistosomiasis in Zambia: a systematic review of past and present experiences. Infect Dis Poverty 2018; 7:41.

44. Knopp S, Person B, Ame SM, et al. Elimination of schistosomiasis transmission in Zanzibar: baseline findings before the onset of a randomized intervention trial. PLoS Negl Trop Dis 2013; 7:e2474.

45. Zambian Ministry of Health. Zambia’s master plan towards the elimination of neglected tropical diseases, 2015 - 2020. Available at: https://www.afro.who.int/sites/default/files/2019-06/Zambia%20NTD%20Master%20Plan%20%202019-2023.pdf. Accessed 30 April 2021.